FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
wasnington,	D.C.	20549	

STATEMENT	OF	CHANGES	IN BEI	NEFICIAL	OWNER	SHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

1. Name and Address of Reporting Person* ENGLE J MELVILLE					2. Issuer Name and Ticker or Trading Symbol Predictive Oncology Inc. [POAI]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
ENGLI	L J MIEL	<u>VILLE</u>			1	<u>urcur</u>	100	11001	<u> </u>		10111				X Direc	tor		10% O	wner
(Last) (First) (Middle)						Date of Earliest Transaction (Month/Day/Year)							1	X Office below	er (give title v)		Other (sbelow)	specify	
8778 E 152ND PLACE					01/0	01/04/2022								CEO and Chairman					
(Street)					4. If A								6. I	Individual or Joint/Group Filing (Check Applicable					
THORN	TON C	0 8	0602												,	filed by On	e Rep	orting Pers	on
(City)	(S	tate) (2	Zip)												Form Perso	filed by Mo on	re thai	n One Rep	orting
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acqu Disposed Of (D) (In 5)					Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following Reported		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)		Price	Transa	ansaction(s) str. 3 and 4)			(111311.4)	
Common Stock 0			01/04/	2022				A		20,428	4	A	\$0	43	3,893		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any				ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		nstr.	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or Nun of						

Explanation of Responses:

/s/ J. Melville Engle

01/05/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.